Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

OPHTHOTECH CORP (OPHT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Robbins Arroyo LLP : Is Investigating the Officers and Directors of Ophthotech Corporation (OPHT) on Behalf of Shareholders

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/13/2017 | 08:13pm CET

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ophthotech Corporation (NasdaqGS: OPHT) breached their fiduciary duties to shareholders. Ophthotech is a biopharmaceutical company that develops novel therapeutics to treat diseases of the back of the eye. The company's lead product candidate is known as Fovista.

View this press release on the firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/ophthotech-corporation-dec-2017/

Ophthotech Accused of Misrepresenting Approval Capacity of Its Drug

Investors of Ophthotech filed a securities class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 11, 2015 and December 12, 2016. According to the complaint, Ophthotech misrepresented Fovista's efficacy and potential for approval by the U.S. Food and Drug Administration. For example, Ophthotech touted that Fovista was "well position[ed] to potentially be first to market in this class of novel therapy for wet [age-related macular degeneration]" and that it had made "significant progress related to [its] clinical development." It came as a surprise to investors when Ophthotech revealed on December 12, 2016 that Fovista, administered in combination with Lucentis, had failed to achieve its primary endpoint in two phase 3 clinical trials. On this news, Ophthotech's stock fell approximately 86% to close at $5.29 per share on December 12, 2016. In a year's time, the company's stock has since fallen even further, closing at only $2.89 per share on December 11, 2017.

Ophthotech Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
12/13 ROBBINS ARROYO LLP : Is Investigating the Officers and Directors of Ophthotech C..
11/09 OPHTHOTECH CORP : Today’s Research Reports on Stocks to Watch: Ophthotech Corpor..
11/08 OPHTHOTECH CORP. : Results of Operations and Financial Condition, Financial Stat..
11/08 OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
11/08 OPHTHOTECH : posts 3Q profit
11/08 OPHTHOTECH : Reports Third Quarter 2017 Financial and Operating Results
11/08 OPHTHOTECH CORP : Ophthotech Corp. to Host Earnings Call
11/07 OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Entry into a Material Defini..
11/07 OPHTHOTECH CORP. : Entry into a Material Definitive Agreement (form 8-K)
10/30 OPHTHOTECH CORPORATION : to Report Third Quarter 2017 Financial Results and Host..
More news
News from SeekingAlpha
12/11 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
12/01 OHR PHARMACEUTICAL : A Compelling Acquisition Candidate And The Best Risk/Reward..
11/08 Ophthotech Corporation 2017 Q3 - Results - Earnings Call Slides
11/08 Ophthotech's (OPHT) CEO Glenn Sblendorio on Q3 2017 Results - Earnings Call T..
11/08 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Financials ($)
Sales 2017 211 M
EBIT 2017 102 M
Net income 2017 103 M
Finance 2017 164 M
Yield 2017 -
P/E ratio 2017 1,05
P/E ratio 2018
EV / Sales 2017 -0,28x
EV / Sales 2018 -0,57x
Capitalization 104 M
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 2,75 $
Spread / Average Target -4,8%
EPS Revisions
Managers
NameTitle
Glenn P. Sblendorio President & Chief Executive Officer
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll Chief Financial Officer & Treasurer
Axel Bolte Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-40.79%104
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385